CD3E and cancer: In 2017, an Fc-free TCE called ATTACK (asymmetric tandem trimerbody for T cell activation and cancer killing) was designed with trivalent and monovalent binding to EGFR and CD3ε, respectively (3 + 1 stoichiometry).